Newcastle-Upon-Tyne and Chapel-en-le-Frith, UK – A pioneering new assay-ready, on-demand chemical supply service has been announced today as the result of a partnership between Molplex and Peakdale Molecular at www.molplex.com.

The new service will radically cut the cost of accessing chemical libraries for drug discovery by providing sophisticated chemical selection systems, allowing customers to choose only those chemicals most likely to be useful and only in the quantity and format they need for a testing.

Eliminating the high start-up costs of chemistry in early drug discovery, the service aims to empower the emerging ecosystem of “Micro Pharmas” by helping them to succeed at inventing new medicines at lower cost.

Molplex CEO, David Leahy said : “Peakdale and Molplex share the same vision of delivering high quality chemical services on demand that enable innovative drug discovery teams to invent new medicines. We’re committed to offering high quality chemical supply services at low cost by using novel technology and allowing customers to order economically and affordably.”

Peakdale CEO, Ray Fisher said, “We have over 25 years experience in providing high quality and knowledgeable chemical synthesis and supply support to the world’s largest pharmaceutical companies. Molplex’s highly innovative on demand drug discovery service puts our high quality chemistry and deep chemical experience at the service of drug discovery teams based anywhere in the world.”

About Molplex

Molplex was created by David Leahy and Vladimir Sykora to help anyone anywhere in the world invent new medicines by making sophisticated drug discovery information and laboratory systems available on-line and on demand. CEO David Leahy previously founded Cyprotex PLC, now the world’s largest ADME Tox service supplier. COO Dr Vladimir Sykora has extensive drug discovery experience and has developed sophisticated software systems for automated drug design. They are joined as VP for Asia-Pacific by Dr Brian O’Keeffe who has considerable commercial and senior management experience in drug development including as President Asia-Pacific for Quintiles.